Effect of urinary catheter securement band on meatal pressure injury in male intensive care patients: A randomized controlled trial.

Intensive Crit Care NursMay 20, 2026 (epub)
Clinical ResearchUrologyInternal Medicine (General)Emergency Medicine

Merve Zorlu, Yasemin Uslu

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effectiveness of a urinary catheter securement band in preventing meatal pressure injury (meatal-PI) among 248 male ICU patients. The intervention group using the securement band had a significantly lower incidence of meatal-PI at 6.5% compared to 16.1% in the control group (p = 0.016).

Key findings

  • The incidence of meatal-PI was 6.5% in the intervention group versus 16.1% in the control group.
  • Catheter securement, silicone catheter use, and shorter ICU stays were identified as protective factors.
  • Advanced age was associated with an increased risk of meatal-PI.
  • Comorbidities and lower Glasgow Coma Scale scores were significantly linked to meatal-PI.

Why it matters

Preventing meatal pressure injuries is crucial in intensive care settings, as these injuries can lead to significant morbidity. This study highlights the potential of catheter securement bands to enhance patient safety and reduce device-related complications.

Source

PubMed · PMID 42161215

Published in Intensive Crit Care Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Urology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.